MX2018011306A - Vector multimodal para infeccion de celulas dentriticas. - Google Patents
Vector multimodal para infeccion de celulas dentriticas.Info
- Publication number
- MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- antigens
- cancer
- dendritic cell
- specific
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 abstract 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 102100022339 Integrin alpha-L Human genes 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310551P | 2016-03-18 | 2016-03-18 | |
| US201662313596P | 2016-03-25 | 2016-03-25 | |
| PCT/US2017/023117 WO2017161360A2 (en) | 2016-03-18 | 2017-03-20 | Multimodal vector for dendritic cell infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011306A true MX2018011306A (es) | 2019-08-16 |
Family
ID=59850551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011306A MX2018011306A (es) | 2016-03-18 | 2017-03-20 | Vector multimodal para infeccion de celulas dentriticas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210198689A1 (enExample) |
| EP (1) | EP3430148A4 (enExample) |
| JP (1) | JP2019508044A (enExample) |
| KR (1) | KR20180118198A (enExample) |
| CN (1) | CN109312364A (enExample) |
| AU (1) | AU2017233072B2 (enExample) |
| CA (1) | CA3016389A1 (enExample) |
| IL (1) | IL261812A (enExample) |
| MX (1) | MX2018011306A (enExample) |
| SG (1) | SG11201808058PA (enExample) |
| WO (1) | WO2017161360A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201414021D0 (en) | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| DK3288573T3 (da) | 2015-04-30 | 2020-03-16 | Psioxus Therapeutics Ltd | Onkolytisk adenovirus, der koder for et b7-protein |
| AU2016311444B2 (en) | 2015-08-25 | 2019-02-07 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
| US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
| KR20210010678A (ko) | 2016-06-30 | 2021-01-27 | 난트 홀딩스 아이피, 엘엘씨 | 난트 암 백신 |
| US12653874B2 (en) | 2016-06-30 | 2026-06-16 | Immunitybio, Inc. | Nant cancer vaccine |
| KR102491752B1 (ko) | 2016-08-29 | 2023-01-26 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| AU2018277294B2 (en) | 2017-06-01 | 2025-04-24 | Akamis Bio Limited | Oncolytic virus and method |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU774076C (en) * | 1998-12-09 | 2005-04-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ES2404689T3 (es) * | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| EP1441758A2 (de) * | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle |
| WO2005035773A2 (en) * | 2003-10-08 | 2005-04-21 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
| CN1761757A (zh) * | 2003-01-07 | 2006-04-19 | 香港大学 | 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤 |
| WO2006108241A1 (en) * | 2005-04-14 | 2006-10-19 | The University Of Queensland | Immunomodulating compositions and uses therefor |
| RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| DK2751279T3 (da) * | 2011-08-31 | 2017-11-20 | St Jude Children's Res Hospital | Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse |
| CN102533859A (zh) * | 2012-01-12 | 2012-07-04 | 中国人民解放军第二军医大学 | 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用 |
| JP6430949B2 (ja) * | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法 |
| EP3524262A1 (en) * | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vectors for expression of prostate-associated antigens |
| JP6535337B2 (ja) * | 2013-11-05 | 2019-06-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| DK3142690T3 (da) * | 2014-05-13 | 2022-05-09 | Bavarian Nordic As | Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist |
-
2017
- 2017-03-20 AU AU2017233072A patent/AU2017233072B2/en not_active Ceased
- 2017-03-20 EP EP17767693.9A patent/EP3430148A4/en not_active Withdrawn
- 2017-03-20 US US16/081,014 patent/US20210198689A1/en not_active Abandoned
- 2017-03-20 MX MX2018011306A patent/MX2018011306A/es unknown
- 2017-03-20 CN CN201780017523.9A patent/CN109312364A/zh active Pending
- 2017-03-20 CA CA3016389A patent/CA3016389A1/en not_active Abandoned
- 2017-03-20 KR KR1020187028404A patent/KR20180118198A/ko not_active Ceased
- 2017-03-20 WO PCT/US2017/023117 patent/WO2017161360A2/en not_active Ceased
- 2017-03-20 JP JP2018546653A patent/JP2019508044A/ja active Pending
- 2017-03-20 SG SG11201808058PA patent/SG11201808058PA/en unknown
-
2018
- 2018-09-16 IL IL261812A patent/IL261812A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210198689A1 (en) | 2021-07-01 |
| CA3016389A1 (en) | 2017-09-21 |
| EP3430148A2 (en) | 2019-01-23 |
| IL261812A (en) | 2018-10-31 |
| JP2019508044A (ja) | 2019-03-28 |
| SG11201808058PA (en) | 2018-10-30 |
| WO2017161360A4 (en) | 2017-11-16 |
| WO2017161360A2 (en) | 2017-09-21 |
| EP3430148A4 (en) | 2020-01-01 |
| AU2017233072A1 (en) | 2018-09-13 |
| WO2017161360A3 (en) | 2017-10-26 |
| CN109312364A (zh) | 2019-02-05 |
| AU2017233072B2 (en) | 2020-12-24 |
| KR20180118198A (ko) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017161360A3 (en) | Multimodal vector for dendritic cell infection | |
| BR112017003718A2 (pt) | inibidores macrocíclicos das interações de proteína/proteína de pd-1/pd-l1 e cd80(b7-1)/pd-l1 | |
| MX2020003526A (es) | Una plataforma universal para la preparación de un receptor antigénico quimérico inhibidor (icar). | |
| MX2025009055A (es) | Vectores de neoantigeno de alfavirus | |
| BR112019010565A2 (pt) | aplicação viral de neoantígenos | |
| BR112017016039A2 (pt) | imunomoduladores. | |
| MX2017011960A (es) | Inmunomoduladores. | |
| MX379487B (es) | Inmunomoduladores. | |
| BR112017012704A2 (pt) | imunomoduladores | |
| PH12015502027A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1) / pd-l1 protein / protein interactions | |
| MX2017007677A (es) | Inmunomoduladores. | |
| EA201892243A1 (ru) | Макроциклические ингибиторы белок/белкового взаимодействия pd-1/pd-l1 и cd80/pd-l1 | |
| UY36400A (es) | Péptidos macrocíclicos como inhibidores de las interacciones entre las proteínas pd-1/pd-l1 y cd80/pd-l1 y sus funciones inmunomoduladoras | |
| EA201790695A1 (ru) | Иммуномодуляторы | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| BR112017011582A2 (pt) | fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina. | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| BR112017016681A2 (pt) | vetor de coexpressão de vacina e moléculas coestimulatórias | |
| CO2019009815A2 (es) | Combinaciones farmacéuticas | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| BR112017006680A2 (pt) | variantes de vírus influenza a | |
| AR113124A1 (es) | Sistema de expresión de paramyxoviridae | |
| UY35733A (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c. | |
| MX2020013551A (es) | Combinaciones farmaceuticas. | |
| CL2017000601A1 (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1 |